Tagged with Opinion

Global Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI into healthcare.   Artificial intelligence (AI) has already begun transforming the healthcare industry, with applications ranging from diagnostics to drug…

Europe James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe.   In an era where artificial intelligence (AI) is revolutionizing healthcare and clinical research, regulatory bodies are racing to keep pace. The…

Global Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.   As pharma companies gear up for another year – a year that marks a quarter of the way through…

India Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for pharmaceuticals are impacting the industry.   Since 2001, the regulatory environment for clinical research and drug development in India has…

Africa John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into Africa have yet to reach fruition.   Recent pandemics have triggered calls for deglobalization in the production of medical products…

Global IFPMA represents the innovative pharmaceutical industry at the international level and in official relations with the United Nations. Dr David Reddy joined the association earlier this year, and shares his analysis on how vaccines and treatments are transforming health outcomes for people around the world, and how the pipeline of…

Global Scott D. Ramsey of the Fred Hutchinson Cancer Center discusses the trend driving pharmaceutical companies to reorganize or eliminate their health economics and outcomes research (HEOR) groups. The original version of this article was featured in the September/October edition of ISPOR’s Value & Outcomes Spotlight magazine.   Last spring, I had…

Global Dr Catherine Duggan, CEO of the International Pharmaceutical Federation, lays out how mental health systems must shift from reactive crisis intervention to proactive, patient-centered approaches; why traditional care models need reimagined funding that prioritises community mental health services and incentivises innovation; and the vital role that pharmacists, as accessible healthcare…

Global Aitia Bio’s Colin Hill, writing in the November 2024 issue of DIA’s Global Forum magazine outlines why “digital twins” – virtual models of patients, systems, or devices that simulate real-world data to predict outcomes, optimize treatments, and improve patient care – have the potential to reshape the entire drug development…

Singapore Writing in the November 2024 edition of DIA’s Global Forum magazine, Johnson & Johnson’s Sandy Chan looks at the fast-evolving regulatory framework for medicines in the dynamic Asia-Pacific region.   Asia Pacific (AP) is an immensely diverse and dynamic region with varying regulatory capabilities and capacities; consequently, AP regulators and…

USA As Breast Cancer Awareness Month 2024 draws to a close, PhRMA’s Elizabeth Carpenter lays out the massive progress made in breast cancer treatment outcomes over the past half-century. However, Carpenter warns that further progress in breast cancer R&D is under threat, highlighting three key policy barriers that must be removed…

USA Monica Weldon, a seasoned rare disease patient advocate in the US, now serves as the lead strategic analyst for the life science industry base policy at Leidos, a technology solutions firm. Here, she explains the rationale behind the Biden administration’s Executive Order 14081 from 2022, as well as its impact…